{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:04Z","timestamp":1791414124289,"version":"4.3.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1093\/jac\/dkm291","type":"journal-article","created":{"date-parts":[[2007,8,30]],"date-time":"2007-08-30T01:15:03Z","timestamp":1188436503000},"page":"994-998","source":"Crossref","is-referenced-by-count":48,"title":["Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis"],"prefix":"10.1093","volume":"60","author":[{"given":"Oluwabunmi Y.","family":"Saliu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catina","family":"Crismale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan K.","family":"Schwander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"key":"key\n\t\t\t\t20170425183455_DKM291C1","first-page":"1","article-title":"Global alliance for TB drug development. Scientific blueprint for tuberculosis drug development","volume":"81","author":"O'Brien","year":"2001","journal-title":"Tuberculosis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jac\/19.4.475","article-title":"Significance of in-vitro penicillin tolerance in experimental enterococcal endocarditis","volume":"19","author":"Kim","year":"1987","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"key\n\t\t\t\t20170425183455_DKM291C3","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1093\/clinids\/8.Supplement_3.S279","article-title":"Phenotypic tolerance: the search for \u03b2-lactam antibiotics that kill nongrowing bacteria","volume":"8","author":"Tuomanen","year":"1986","journal-title":"Rev Infect Dis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C4","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1128\/AAC.43.11.2600","article-title":"Drug tolerance in Mycobacterium tuberculosis","volume":"43","author":"Wallis","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183455_DKM291C5","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170425183455_DKM291C6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.4049\/jimmunol.160.5.2408","article-title":"Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects","volume":"160","author":"Silver","year":"1998","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170425183455_DKM291C7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/ajrccm\/147.4.1062","article-title":"Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]","volume":"147","author":"Mitchison","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C8","first-page":"95","article-title":"Surrogate markers to assess clinical efficacy of new antituberculous drugs","volume-title":"The Development of New Antituberculosis Drugs","author":"Wallis","year":"2006"},{"key":"key\n\t\t\t\t20170425183455_DKM291C9","first-page":"155","article-title":"Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis","volume":"86","author":"Botha","year":"1996","journal-title":"S Afr Med J"},{"key":"key\n\t\t\t\t20170425183455_DKM291C10","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1547","article-title":"Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis","volume":"148","author":"Kennedy","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/32.6.867","article-title":"The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment","volume":"32","author":"Sirgel","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425183455_DKM291C13","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/AAC.40.10.2296","article-title":"Bactericidal action of ofloxacin, sulbactam\u2013ampicillin, rifampicin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis","volume":"40","author":"Herbert","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425183455_DKM291C14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/430914","article-title":"Reconsidering adjuvant immunotherapy for tuberculosis","volume":"41","author":"Wallis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C15","first-page":"367","article-title":"Experimental models to explain the high sterilizing activity of rifampicin in the chemotherapy of tuberculosis","volume":"123","author":"Dickinson","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20170425183455_DKM291C16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.20040646","article-title":"Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice","volume":"200","author":"Karakousis","year":"2004","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170425183455_DKM291C17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jac\/46.6.917","article-title":"Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG","volume":"46","author":"Murugasu-Oei","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425183455_DKM291C18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1099\/mic.0.26234-0","article-title":"pckA -deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages","volume":"149","author":"Liu","year":"2003","journal-title":"Microbiology"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/60\/5\/994\/13758908\/dkm291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T23:25:25Z","timestamp":1684020325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkm291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,29]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2007,8,29]]},"published-print":{"date-parts":[[2007,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkm291","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8,29]]}}}